A cost analysis of upfront DPYD genotype-guided dose individualisation in fluoropyrimidine-based anticancer therapy

Author(s):
Henricks, L.M. (0000-0003-0141-7927); Lunenburg, C.A.T.C. (0000-0003-0173-9803); Man, F.M. de; Meulendijks, D.; Frederix, G.W.J.; Kienhuis, E.; Creemers, G.J.; Baars, A.; Dezentje, V.O.; Imholz, A.L.T.; Jeurissen, F.J.F.; Portielje, J.E.A.; Jansen, R.L.H.; Hamberg, P.; Tije, A.J. ten; Droogendijk, H.J.; Koopman, M.; Nieboer, P.; Poel, M.H.W. van de; Mandigers, C.M.P.W.; Rosing, H.; Beijnen, J.H.; Werkhoven, E. van; Kuilenburg, A.B.P. van; Schaik, R.H.N. van; Mathijssen, R.H.J.; Swen, J.J.; Gelderblom, H.; Cats, A.; Guchelaar, H.J. (0000-0002-7085-1383); Schellens, J.H.M.
Published
2019
Publication type
Article / Letter to editor
Cost-analysisDihydropyrimidine dehydrogenaseDPYDPharmacogeneticsFluoropyrimidinesGenotypingToxicity
Date issued
2019-01-31
Language
English
Is part of
European Journal of Cancer (2019), Vol. 107, p. 60-67
hdl
1887/119507
doi
10.1016/j.ejca.2018.11.010